RPRX Royalty Pharma
- 26.850
- -0.480-1.76%
- 27.140
- +0.290+1.08%
Royalty Pharma News
Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)
B of A Securities: Maintaining the Royalty Pharma (RPRX.US) rating, adjusted from buy to buy rating, and adjusted target price from $40.00 to $38.00.
Royalty Pharma Analyst Ratings
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating
Royalty Pharma Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Royalty Pharma (RPRX), Pro Medicus Limited (PMCUF)
Goldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)
Buy Rating Affirmed for Royalty Pharma on Strong Financials and Growth Prospects
Buy Rating Affirmed for Royalty Pharma on Strong Growth and Strategic Positioning
Analysts Are Bullish on Top Healthcare Stocks: Incyte (INCY), Royalty Pharma (RPRX)
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $57
Royalty Pharma Analyst Ratings
Strong Q3 Performance and Positive Outlook Boosts Royalty Pharma's Buy Rating: An Analysis by Chris Shibutani
Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Bristol-Myers Squibb (BMY) and Edwards Lifesciences (EW)
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $54
Royalty Pharma Analyst Ratings
Goldman Sachs Sticks to Its Buy Rating for Royalty Pharma (RPRX)
Goldman Sachs Keeps Their Buy Rating on Royalty Pharma (RPRX)
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating
Analysis
Price Target
No Data
